Liver Cancer BCLC Staging: How Is It Assessed in 2026?

BCLC staging is a liver cancer-specific staging system that combines tumor factors — size, number, and vascular invasion — with liver function (Child-Pugh grade) and overall performance status to guide treatment direction. Even tumors of the same size can have different available treatments depending on liver function.

Key Takeaways

• Liver cancer treatment decisions aren't based on TNM staging alone. Staging systems like BCLC combine three factors: tumor status, liver function (Child-Pugh grade), and overall performance status.
• Broadly, stages break down into very early/early (resection, ablation, or transplant eligible), intermediate (multiple tumors confined to the liver, embolization-centered), advanced (vascular invasion or spread beyond the liver, drug therapy-centered), and terminal (declining liver function, symptom management-centered).
• Even tumors of the same size can qualify for different treatments depending on liver function, so liver function test results — bilirubin, albumin, coagulation values — are just as central to review as imaging.
• Korea's 5-year relative survival rate for liver cancer is 40.4% (National Cancer Registration Statistics, 2019–2023). This is a national aggregate figure, not a prediction for any individual's outcome.
• Survival rates and staging interpretations reflect national statistics, not any single institution's results. The actual treatment sequence is determined through discussion with your medical team.

What Factors Determine BCLC Staging?

• BCLC (Barcelona Clinic Liver Cancer) staging is a liver cancer-specific system that combines tumor factors, liver function, and overall performance status. Because liver cancer usually arises on top of chronic hepatitis or cirrhosis, treatment can't be decided by tumor size and number alone — whether the liver itself can tolerate surgery or procedures must also be factored in.
• Specifically, three elements are assessed together: first, the number, size, and vascular invasion status of tumors; second, liver function evaluated via Child-Pugh grade, which combines bilirubin, albumin, coagulation values, ascites, and jaundice; and third, the patient's overall performance status. If any one of these three is poor, the range of available treatments narrows even for a tumor of the same size.

How Does Treatment Differ by BCLC Stage?

• In very early/early stages (small tumor, few in number, good liver function), liver resection is the first choice. When resection is difficult due to tumor location or liver function, radiofrequency ablation is used to burn away the tumor. If liver function has declined significantly but tumor size and number fall within criteria, liver transplantation becomes the definitive treatment.
• In intermediate stages (multiple tumors confined within the liver), transarterial chemoembolization (TACE), which blocks the blood vessels feeding the tumor, is the central approach. Combinations with radioembolization or stereotactic radiotherapy/particle therapy, or leading with systemic drug therapy, are also considered.
• In advanced stages (vascular invasion or spread beyond the liver), systemic drug therapy is central. A combination of an immune checkpoint inhibitor and an angiogenesis inhibitor has become the first-line standard, and oral targeted therapies are used depending on the case.
• In terminal stages with significantly declined liver function, chemotherapy can actually damage the liver further, so the focus shifts to symptom management, preserving liver function, and reassessing transplant eligibility.

What Is the Sequence for Diagnosis and Staging?

• Step 1: In patients with cirrhosis or chronic hepatitis, if contrast-enhanced CT or MRI shows the blood flow pattern characteristic of liver cancer (strong arterial-phase enhancement followed by washout), diagnosis can be made without a biopsy.
• Step 2: Tumor markers such as AFP are checked alongside imaging. Biopsy is performed only when imaging findings are ambiguous or metastasis from another cancer is suspected.
• Step 3: Staging — including BCLC — is determined by combining tumor number, size, and vascular invasion; liver function assessed via Child-Pugh grade; and overall performance status.
• Step 4: Depending on the stage, hepatobiliary-pancreatic surgery, gastroenterology, radiation oncology, and radiology teams jointly determine the treatment pathway — resection, ablation, embolization, radiation, transplant, or drug therapy.

FAQ — Can BCLC Stage and Treatment Plan Change?

In cases such as repeated embolization procedures showing diminishing response, a shift toward systemic drug therapy or radiotherapy can be considered based on how the patient responds during treatment. The number and extent of embolization procedures received so far, along with imaging records from each session, serve as the basis for determining the next step.

FAQ — Does the Survival Rate Figure Directly Apply to My Stage?

No. Korea's 5-year relative survival rate of 40.4% for liver cancer (National Cancer Registration Statistics, 2019–2023) and the SEER-based U.S. figure of 21.9% (2016–2022) are both national aggregate statistics, not figures from any specific institution. Even within the same stage, liver cancer outcomes and recommended treatments vary significantly depending on liver function, portal pressure, and hepatitis status, making these numbers unreliable as predictors of an individual's outcome.

Sources and Notes

• This article was written based on general explanations drawn from the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea), SEER 2016–2022, the National Cancer Information Center, and NCCN patient guideline-level information.
• This content is provided for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult your medical team to determine an accurate diagnosis and treatment plan.